IP Organiser’s recently compiled record of every pharmaceutical patent term extension granted in Australia maps roughly 1,600 extended patents across 850 products, and the patterns are worth reading closely. Activity is concentrated: a handful of originators (Novartis well out in front, then Pfizer, Roche, AstraZeneca and GSK) and just four attorney firms account for around three-quarters of all filings.
The portfolio has also shifted decisively toward biologics and advanced therapies — antibodies, RNAi agents, cell and gene therapies, radioligands and vaccines — using a regime originally built with small molecules in mind. And extension is not a formality: roughly one in eighteen applications was refused or withdrawn, and filings hit a record in 2025 before continuing into 2026. The window to apply is narrow and the eligibility rules unforgiving; the rights go to those who treat timing as a discipline, not an afterthought.
The extended-expiry dates cluster heavily between 2030 and 2034 and stretch out to 2041 — this is, in effect, a published timetable of when each competitor’s protection lapses and when generic or biosimilar entry opens. That is competitive intelligence for challengers and an early-warning system for incumbents. Look closer and you see the architecture: scores of molecules are defended not by one patent but by three or more separately extended patents layered around formulation, salt forms and methods of use. None of this happens by accident.
Lifecycle protection is engineered years ahead — through disciplined filing strategy, deadline rigour and a deliberate stack of rights — the public record will reveal whether you did it well.
Read the calendar and learn from it before your competitors do.
Here’s the data: https://docs.google.com/spreadsheets/d/1wJ7OIdmSfBxNIjJnRDCBNwp2FEiJY74k/edit?gid=920856139#gid=920856139
Here’s Rodney Cruise’s post in LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:7464445225080557568/